Comparable stake leader
BIOTECHNOLOGY VALUE FUND L P
SEC ownership of Eledon Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001404281.
Disclosed value leader
BIOTECHNOLOGY VALUE FUND L P
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- ELDN on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BIOTECHNOLOGY VALUE FUND L P
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BIOTECHNOLOGY VALUE FUND L P
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001404281
- Issuer location
- Irvine, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Eledon Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BIOTECHNOLOGY VALUE FUND L P
Disclosed value leader
BIOTECHNOLOGY VALUE FUND L P
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
13D/G row: BIOTECHNOLOGY VALUE FUND L P
Showing 1-8 of 50 holder rows.
Quick read
BIOTECHNOLOGY VALUE FUND L P leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BIOTECHNOLOGY VALUE FUND L P's linked filing trail.
Comparable ownership
Top 5
BIOTECHNOLOGY VALUE FUND L P
10%
BlackRock, Inc.
5.8%
VANGUARD CAPITAL MANAGEMENT LLC
5%
ARMISTICE CAPITAL, LLC
5%
Coastlands Capital LP
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
|
$25,336,309
7,868,419 shares
|
$0 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.8%
from 13D/G
|
$20,187,937
5,123,842 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5%
|
$16,100,582
3,898,446 shares
|
$0 | 30 Jun 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$10,259,798
3,137,553 shares
|
$0 | 31 Dec 2024 |
| Coastlands Capital LP |
13D/G
|
5%
|
$6,733,682
3,937,826 shares
|
-$1,410,519 | 31 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
James N. Topper
|
2%
|
$3,847,923
1,176,735 shares
|
$0 | 31 Dec 2024 |
| Keith Katkin |
3/4/5
Director
|
0.01%
|
$12,948
8,575 shares
|
— | 10 Jan 2026 |
| Allan Kirk PhD |
3/4/5
Director
|
0%
|
$5,179
3,430 shares
|
— | 10 Jan 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to Eledon Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
BVF PARTNERS L P/IL
Net 12M change
$0
Latest report
31 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| BVF PARTNERS L P/IL | 10%+ Owner | $4,047,373 | Mixed | 29 Oct 2024 | ||
| Gary A. Lyons | Director | $673,958 | Mixed | 01 May 2023 | ||
| David-Alexandre C. Gros | Chief Executive Officer, Director | $664,532 | Median | 31 Jul 2026 | ||
| Ph.D. Steven Perrin | President, Director | $319,987 | Median | 31 Jul 2026 | ||
| Keith Katkin | Director | $12,948 | Mixed | 10 Jan 2026 | ||
| John S. McBride | Director | $5,179 | Mixed | 10 Jan 2026 | ||
| James A. Robinson Jr. | Director | $5,179 | Mixed | 10 Jan 2026 | ||
| June Lee | Director | $5,179 | Mixed | 10 Jan 2026 | ||
| Jan Hillson | Director | $5,179 | Mixed | 10 Jan 2026 | ||
| Allan Kirk PhD | Director | $5,179 | Mixed | 10 Jan 2026 | ||
| Paul Sean Little | Chief Financial Officer | Mixed | 10 Jan 2025 | |||
| Walter C. Ogier | Director | Mixed | 01 May 2023 | |||
| Bryan E. Smith | General Counsel, Corporate Sec | Mixed | 10 Jan 2025 |
Recent insider transactions for Eledon Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| James A. Robinson Jr. | ELDN | Stock Option (right to buy) | Award | 30,870 | 30,870 | 10 Jan 2035 | Direct | |||
| David-Alexandre C. Gros | ELDN | Common Stock | Tax liability | -53.6% | -194,791 | 168,663 | 31 Jul 2026 | Direct | ||
| David-Alexandre C. Gros | ELDN | Common Stock | Award | 3938.4% | 354,454 | 363,454 | 31 Jul 2026 | Direct | ||
| Ph.D. Steven Perrin | ELDN | Common Stock | Tax liability | -47% | -72,138 | 81,215 | 31 Jul 2026 | Direct | ||
| Ph.D. Steven Perrin | ELDN | Common Stock | Award | 15235.3% | 152,353 | 153,353 | 31 Jul 2026 | Direct | ||
| John S. McBride | ELDN | Common Stock | Options Exercise | 3,430 | 3,430 | 10 Jan 2026 | Direct | |||
| John S. McBride | ELDN | Restricted Stock Units | Options Exercise | -100% | -3,430 | 0 | 10 Jan 2026 | Direct | ||
| Jan Hillson | ELDN | Common Stock | Options Exercise | 3,430 | 3,430 | 10 Jan 2026 | Direct | |||
| Jan Hillson | ELDN | Restricted Stock Units | Options Exercise | -100% | -3,430 | 0 | 10 Jan 2026 | Direct | ||
| Allan Kirk PhD | ELDN | Common Stock | Options Exercise | 3,430 | 3,430 | 10 Jan 2026 | Direct | |||
| Allan Kirk PhD | ELDN | Restricted Stock Units | Options Exercise | -100% | -3,430 | 0 | 10 Jan 2026 | Direct | ||
| Keith Katkin | ELDN | Common Stock | Options Exercise | 8,575 | 8,575 | 10 Jan 2026 | Direct | |||
| Keith Katkin | ELDN | Restricted Stock Units | Options Exercise | -100% | -8,575 | 0 | 10 Jan 2026 | Direct | ||
| June Lee | ELDN | Common Stock | Options Exercise | 3,430 | 3,430 | 10 Jan 2026 | Direct | |||
| June Lee | ELDN | Restricted Stock Units | Options Exercise | -100% | -3,430 | 0 | 10 Jan 2026 | Direct | ||
| James A. Robinson Jr. | ELDN | Common Stock | Options Exercise | 3,430 | 3,430 | 10 Jan 2026 | Direct | |||
| James A. Robinson Jr. | ELDN | Restricted Stock Units | Options Exercise | -100% | -3,430 | 0 | 10 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.